HER2 positivity was considered an independent prognostic indicator of patient survival and is correlated with a number of adverse prognostic factors in breast cancer including increased occurrence of metastasis and micrometastatic bone marrow disease [35]. Here, ERBB2 is linked to bone marrow disorder.